tldrdailynews.com logo
Tag

Glp 1 Receptor Agonists

All articles tagged with #glp 1 receptor agonists

Weight-Loss Drugs Show Long-Term Heart Benefits Across High-Risk Patients
health24 days ago

Weight-Loss Drugs Show Long-Term Heart Benefits Across High-Risk Patients

A meta-analysis of 11 cardiovascular outcome trials (over 90,000 patients) finds GLP-1 receptor agonists reduce major cardiovascular events and all-cause mortality by about 13% over an average follow-up of nearly three years, with benefits seen in high-risk groups including those with or without diabetes. While GI side effects (nausea, vomiting) are more common, no significant safety signals like pancreatitis or hypoglycemia emerged. The results suggest these obesity/diabetes drugs may play a broader role in cardiovascular risk reduction and could influence clinical practice and policy.

via SciTechDaily|
#cardiovascular-disease#diabetes#glp-1-receptor-agonists
GLP-1 Diabetes Drugs Target Alzheimer’s Pathology in Animal Studies
science1 month ago

GLP-1 Diabetes Drugs Target Alzheimer’s Pathology in Animal Studies

A systematic review of 30 preclinical studies finds GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide) consistently reduce Alzheimer's hallmarks amyloid-beta plaques and tau tangles in animal and cell models, with liraglutide showing the strongest and most consistent effects; human data are limited and mixed so far, though some trials show preserved brain glucose metabolism and inflammatory marker changes, suggesting these drugs may help prevent dementia if used earlier rather than cure established disease.

via Neuroscience News|
#alzheimers-disease#amyloid-beta#glp-1-receptor-agonists
GLP-1 Diabetes Drugs Linked to Higher Long-Term Cognitive Impairment Risk
health1 month ago

GLP-1 Diabetes Drugs Linked to Higher Long-Term Cognitive Impairment Risk

A propensity-matched retrospective study of nearly 65,000 adults with type 2 diabetes found that those treated with GLP-1 receptor agonists had a higher long-term risk of durable cognitive impairment over 10 years (2.6% vs 1.3%), with a hazard ratio of 2.74. The study shows an association, not causation, and further research is needed to determine whether GLP-1 therapy contributes to cognitive decline or reflects underlying risk factors.

via MedPage Today|
#cognition#diabetes#epidemiology
GLP-1 Weight-Loss Drugs: Is Muscle Loss Inevitable?
health1 month ago

GLP-1 Weight-Loss Drugs: Is Muscle Loss Inevitable?

A Nature Reviews Endocrinology commentary reviews potential risks of GLP-1 receptor agonists used for obesity, noting concerns about accelerated muscle wasting and frailty in some patients; it explores mechanisms, aging-related vulnerability, and the need for biomarkers and careful monitoring, while acknowledging mixed evidence and the ongoing need for research to balance fat loss with muscle preservation.

via Nature|
#frailty#glp-1-receptor-agonists#health
GLP-1 diabetes meds may curb worsening anxiety and depression, study finds
health2 months ago

GLP-1 diabetes meds may curb worsening anxiety and depression, study finds

A large Swedish study of about 95,000 people with depression or anxiety who were taking diabetes medications found that GLP-1 receptor agonists—especially semaglutide and liraglutide—were associated with a lower risk of worsening mental health outcomes such as hospitalizations, sick leave, self-harm, or death, while other GLP-1 drugs did not show the same benefit; experts caution about drawing causality from observational data. A separate Danish study linked first-trimester exposure to semaglutide or liraglutide for diabetes with a higher risk of preterm birth.

via The Guardian|
#anxiety#depression#glp-1-receptor-agonists
health4 months ago

GLP-1 Medications Surge in Pregnancy Amid Sparse Safety Data

TriNetX analysis (2019–2024) shows predelivery GLP-1 receptor agonist use rising from 0.2 to 6.4 per 1000 deliveries and postdelivery use from 0.3 to 14.6 per 1000. In 2024, recipients commonly had obesity and anxiety or mood disorders, with gestational diabetes also noted. Semaglutide and tirzepatide were studied. Data are aggregate with limited safety information, prompting clinicians to consider nutritional status and perinatal psychosocial histories in care.

via Medscape|
#gestational-diabetes#glp-1-receptor-agonists#health
MHRA Probes Cancer and Pancreatitis Risks of GLP-1 Drugs Like Ozempic
health9 months ago

MHRA Probes Cancer and Pancreatitis Risks of GLP-1 Drugs Like Ozempic

Concerns are rising over potential cancer links, especially thyroid cancer, associated with weight loss drugs like Ozempic and Mounjaro, which are GLP-1 receptor agonists. While these drugs aid weight loss and improve metabolic health, their long-term safety remains uncertain, with limited evidence suggesting possible risks. They are not recommended for individuals with a history of thyroid cancer or certain genetic conditions, and more research is needed to fully understand their safety profile.

via ScienceAlert|
#cancer-risk#glp-1-receptor-agonists#health
Weight Loss Injections May Undermine Breast Cancer Treatment
health1 year ago

Weight Loss Injections May Undermine Breast Cancer Treatment

Experts warn that weight loss drugs like Ozempic and Wegovy, known as GLP-1 receptor agonists, may reduce the effectiveness of chemotherapy and immunotherapy in treating aggressive breast cancer. A study found that women on these drugs were less likely to be cancer-free after treatment, with only 28% responding fully compared to 63% not on the drugs. Researchers suggest careful consideration of GLP-1 use during cancer therapy, as these drugs may make tumor cells more resistant to standard treatments.

via Daily Mail|
#breast-cancer#cancer-treatment#chemotherapy
Obesity Drugs: Why 1 in 5 Don't See Results and Potential Risks
health1 year ago

Obesity Drugs: Why 1 in 5 Don't See Results and Potential Risks

Despite the popularity of obesity drugs like Wegovy and Ozempic, not all patients experience significant weight loss, with up to 20% being nonresponders. Factors such as genetics, hormones, and medical conditions can influence the effectiveness of these GLP-1 receptor agonists. Experts emphasize the need for personalized treatment plans and caution against expecting uniform results. Patients like Danielle Griffin, who saw minimal weight loss, may need to explore alternative medications or lifestyle changes to achieve their goals.

via VINNews|
#glp-1-receptor-agonists#health#healthcare
Ozempic and Wegovy: Potential Allies in Reducing Alcohol Consumption
health1 year ago

Ozempic and Wegovy: Potential Allies in Reducing Alcohol Consumption

Research from the University of Nottingham suggests that GLP-1 receptor agonists, a class of diabetes medications, may help reduce alcohol consumption, particularly in individuals with obesity. The study, published in eClinicalMedicine, reviewed data from trials involving over 88,000 participants and found that while results vary, some individuals showed significant benefits. The findings indicate potential for these medications to target the brain's reward center, offering a future treatment option for excessive alcohol use.

via SciTechDaily|
#alcohol-consumption#diabetes#glp-1-receptor-agonists
Bariatric Surgery Outperforms GLP-1 Drugs and Lifestyle Changes in Weight Loss and Mortality Reduction
health1 year ago

Bariatric Surgery Outperforms GLP-1 Drugs and Lifestyle Changes in Weight Loss and Mortality Reduction

A systematic review from 2020 to 2024 reveals that bariatric surgery offers the most sustained and significant weight loss, maintaining about 25% weight loss for up to 10 years, compared to GLP-1 receptor agonists and lifestyle changes. Despite its effectiveness, bariatric surgery remains underutilized in treating severe obesity.

via SciTechDaily|
#bariatric-surgery#glp-1-receptor-agonists#health
Weight-Loss Drugs Slash Cancer Risk by 20%, Study Finds
health2 years ago

Weight-Loss Drugs Slash Cancer Risk by 20%, Study Finds

Research presented at the world's largest cancer conference shows that weight-loss drugs, particularly GLP-1 receptor agonists like Wegovy, can reduce the risk of developing obesity-related cancers by 19% and potentially halve the mortality rate over 15 years. These findings suggest that such drugs could play a significant role in cancer prevention and treatment, although further well-designed trials are needed to confirm their safety and efficacy.

via The Guardian|
#cancer-prevention#glp-1-receptor-agonists#health